A journal article reported an association between anti-HBc and NANBH and that a high percentage of NANBH patients develop chronic hepatitis. It concluded that if surrogate screening could prevent approximately one third of transfusion-associated cases of NANBH, this could represent an annual reduction of 50,000 cases of hepatitis and 2,500 cases of cirrhosis in the US. Read more about A journal article reported an association between anti-HBc and NANBH and that a high percentage of NANBH patients develop chronic hepatitis. It concluded that if surrogate screening could prevent approximately one third of transfusion-associated cases of NANBH, this could represent an annual reduction of 50,000 cases of hepatitis and 2,500 cases of cirrhosis in the US.
Dr Forrester asked the Communicable Diseases Surveillance Unit in Glasgow for information on the likely incidence of NANBH in Scotland, the proportion of NANBH attributable to blood transfusion or administration of blood, and how far any proposed test could reduce this proportion. Read more about Dr Forrester asked the Communicable Diseases Surveillance Unit in Glasgow for information on the likely incidence of NANBH in Scotland, the proportion of NANBH attributable to blood transfusion or administration of blood, and how far any proposed test could reduce this proportion.
Dr Forrester appeared sceptical about the introduction of surrogate screening which was reflected in his note on SNBTS Directors' meeting where he commented that there was "no justification for panic measures." Read more about Dr Forrester appeared sceptical about the introduction of surrogate screening which was reflected in his note on SNBTS Directors' meeting where he commented that there was "no justification for panic measures."
Dr Brian McClelland stated he would provide data on raised ALT levels in blood donors by Autumn 1986. The SNBTS directors agreed to consider funding Read more about Dr Brian McClelland stated he would provide data on raised ALT levels in blood donors by Autumn 1986. The SNBTS directors agreed to consider funding
Dr Gerald Sandler informed Dr Cash that the American Red Cross had not changed its approach to donor testing but would review whether to introduce anti-HBc/ALT donor testing imminently. Read more about Dr Gerald Sandler informed Dr Cash that the American Red Cross had not changed its approach to donor testing but would review whether to introduce anti-HBc/ALT donor testing imminently.
Dr Cash asked Dr Gerald Sandler the outcome of the FDA's deliberations and whether the American Red Cross had decided to introduce routine anti-HBc testing of donations. Read more about Dr Cash asked Dr Gerald Sandler the outcome of the FDA's deliberations and whether the American Red Cross had decided to introduce routine anti-HBc testing of donations.
In a publication Dr Alter and Dr Leonard Seeff made reference to a study conducted in Germany, which measured the impact of adding anti-HBc testing to the screening of a population already tested for ALT. It showed that recipients of anti-HBc positive blood had a five-fold greater risk of developing post-transfusion hepatitis than recipients of blood testing negative. Read more about In a publication Dr Alter and Dr Leonard Seeff made reference to a study conducted in Germany, which measured the impact of adding anti-HBc testing to the screening of a population already tested for ALT. It showed that recipients of anti-HBc positive blood had a five-fold greater risk of developing post-transfusion hepatitis than recipients of blood testing negative.
Dr Alter and Dr Dienstag stated in an article on Non-A, Non-B Hepatitis that "the accumulating data that chronic NANB hepatitis leads to cirrhosis in 10 to 20% of cases has served as compelling evidence for the need to rely on indirect assays as an interim measure until such time as specific NANB hepatitis assays are developed." Read more about Dr Alter and Dr Dienstag stated in an article on Non-A, Non-B Hepatitis that "the accumulating data that chronic NANB hepatitis leads to cirrhosis in 10 to 20% of cases has served as compelling evidence for the need to rely on indirect assays as an interim measure until such time as specific NANB hepatitis assays are developed."
Dr Dow stated that he thought surrogate testing would have been likely to reduce the incidence of post-transfusion NANBH in Scotland by 70 percent. Read more about Dr Dow stated that he thought surrogate testing would have been likely to reduce the incidence of post-transfusion NANBH in Scotland by 70 percent.
Dr Dow concluded in his PhD thesis on Non-A, Non-B Hepatitis in West Scotland that transfusion associated NANBH was very rare, an average of 3 reported cases were reported annually. Read more about Dr Dow concluded in his PhD thesis on Non-A, Non-B Hepatitis in West Scotland that transfusion associated NANBH was very rare, an average of 3 reported cases were reported annually.